Last reviewed · How we verify
TP 3654
At a glance
| Generic name | TP 3654 |
|---|---|
| Sponsor | Sumitomo Pharma America, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- TP-3654 Food Effect Study (PHASE1)
- A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis (PHASE1, PHASE2)
- Assessment of Relative Bioavailability and Effect of Food on Capsule and Tablet Formulations of TP-3654 (PHASE1)
- Study of TP-3654 in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TP 3654 CI brief — competitive landscape report
- TP 3654 updates RSS · CI watch RSS
- Sumitomo Pharma America, Inc. portfolio CI